What is Testing Matters Toxicology?
Established in 2005, Testing Matters Toxicology operates as a premier laboratory service provider, specializing in a diverse array of diagnostic disciplines including microbiology, toxicology, pathology, and DNA pharmacogenetics. The company distinguishes itself through a rigorous commitment to precision and rapid turnaround times, which are essential for modern clinical decision-making. Beyond its core laboratory operations, the firm maintains a robust Mobile Phlebotomy Department, effectively bridging the gap between complex diagnostic requirements and patient accessibility. By integrating advanced instrumentation with a patient-centric service model, Testing Matters has carved out a defensible market position as a reliable partner for physicians and healthcare facilities requiring high-fidelity diagnostic data.
How much funding has Testing Matters Toxicology raised?
Testing Matters Toxicology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Testing Matters Toxicology
PPP
Public-Private Partnership
What's next for Testing Matters Toxicology?
Looking ahead, the deployment of this capital will likely focus on the modernization of laboratory workflows and the expansion of the company's pharmacogenetics and cancer screening portfolios. As the healthcare sector increasingly shifts toward personalized medicine, Testing Matters is strategically aligned to capitalize on the rising demand for specialized diagnostic insights. The firm's focus on operational efficiency and its established mobile service network provide a scalable foundation for future market penetration. By prioritizing technological integration and service reliability, the company is poised to navigate the complexities of the late-stage growth phase, ensuring sustained value creation for its stakeholders and improved health outcomes for its patient base.
See full Testing Matters Toxicology company page
